| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0002 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0003 |
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0003 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0003 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.1 | 0.0006 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0007 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0007 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0008 |
| mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |